{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T04:04:47Z","timestamp":1779681887976,"version":"3.53.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["NIHR500764"],"award-info":[{"award-number":["NIHR500764"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asian Journal of Psychiatry"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ajp.2026.104979","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T06:26:29Z","timestamp":1776234389000},"page":"104979","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Adjunctive pimavanserin in schizophrenia: A systematic review and meta-analysis with a focus on negative-symptom programmes"],"prefix":"10.1016","volume":"120","author":[{"given":"Samuel Izaias","family":"dos Santos Pereira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabela Borja","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matheus Hissa Louren\u00e7o","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alper","family":"Mert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo Lucas","family":"de Lima Prado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel Oliveira Teixeira","family":"Lyra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia Costa","family":"de Ara\u00fajo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9bora","family":"Xavier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9bora Regina","family":"de Aguiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5037-7792","authenticated-orcid":false,"given":"Nima Norbu","family":"Sherpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajp.2026.104979_bib1","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1523\/JNEUROSCI.22-09-03708.2002","article-title":"Prefrontal dopamine D1 receptors and working memory in schizophrenia","volume":"22","author":"Abi-Dargham","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ajp.2026.104979_bib2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.schres.2016.05.015","article-title":"Treatment of negative symptoms: where do we stand, and where do we go?","volume":"186","author":"Aleman","year":"2017","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.ajp.2026.104979_bib3","series-title":"Diagnostic and statistical manual of mental disorders","article-title":"Arlington, VA","author":"American Psychiatric Association","year":"2013"},{"key":"10.1016\/j.ajp.2026.104979_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v106.i02","article-title":"netmeta: an R package for network meta-analysis using frequentist methods","volume":"106","author":"Balduzzi","year":"2023","journal-title":"J. Stat. Softw."},{"key":"10.1016\/j.ajp.2026.104979_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020508","article-title":"5-HT(2C) receptors localize to dopamine and GABA neurons in the rat mesoaccumbens pathway","volume":"6","author":"Bubar","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ajp.2026.104979_bib6","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S2215-0366(21)00386-2","article-title":"Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe","volume":"9","author":"Bugarski-Kirola","year":"2022","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.ajp.2026.104979_bib7","doi-asserted-by":"crossref","DOI":"10.1093\/schizbullopen\/sgac006","article-title":"ENHANCE: phase 3, randomized, double-blind, placebo-controlled study of adjunctive pimavanserin for schizophrenia in patients with an inadequate response to antipsychotic treatment","volume":"3","author":"Bugarski-Kirola","year":"2022","journal-title":"Schizophr. Bull. Open"},{"key":"10.1016\/j.ajp.2026.104979_bib8","article-title":"A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pimavanserin as an adjunctive treatment for the negative symptoms of schizophrenia (ADVANCE-2) in patients with predominant negative symptoms","author":"Bugarski-Kirola","year":"2025","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.ajp.2026.104979_bib9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3389\/fnint.2013.00025","article-title":"Serotonin modulation of cortical neurons and networks","volume":"7","author":"Celada","year":"2013","journal-title":"Front. Integr. Neurosci."},{"key":"10.1016\/j.ajp.2026.104979_bib10","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson\u2019s disease psychosis: a randomised, placebo-controlled phase 3 trial","volume":"383","author":"Cummings","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ajp.2026.104979_bib11","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0165-1781(96)02870-3","article-title":"A comparison of instrument sensitivity to negative symptom change","volume":"63","author":"Eckert","year":"1996","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.ajp.2026.104979_bib12","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.schres.2015.09.012","article-title":"Measuring motivation in people with schizophrenia","volume":"169","author":"Fervaha","year":"2015","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.ajp.2026.104979_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/bmjment-2023-300771","article-title":"Adjunctive agents to antipsychotics in schizophrenia: a systematic umbrella review and recommendations for amino acids, hormonal therapies and anti-inflammatory drugs","volume":"26","author":"Fond","year":"2023","journal-title":"BMJ Ment. Health"},{"key":"10.1016\/j.ajp.2026.104979_bib14","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/schbul\/sbu170","article-title":"Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials","volume":"41","author":"Fusar-Poli","year":"2015","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.ajp.2026.104979_bib15","article-title":"EPA guidance on treatment of negative symptoms in schizophrenia","volume":"64","author":"Galderisi","year":"2021","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.ajp.2026.104979_bib16","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S2215-0366(18)30050-6","article-title":"Negative symptoms of schizophrenia: new developments and unanswered research questions","volume":"5","author":"Galderisi","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.ajp.2026.104979_bib17","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction\u2014GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.ajp.2026.104979_bib18","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1007\/s11064-014-1293-3","article-title":"On the discovery and development of pimavanserin: a novel drug candidate for Parkinson\u2019s psychosis","volume":"39","author":"Hacksell","year":"2014","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.ajp.2026.104979_bib19","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2147\/PROM.S454845","article-title":"Systematic literature review of studies reporting measures of functional outcome or quality of life in people with negative symptoms of schizophrenia","volume":"15","author":"Hadzi Boskovic","year":"2024","journal-title":"Patient Relat. Outcome Meas."},{"key":"10.1016\/j.ajp.2026.104979_bib20","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/wps.20647","article-title":"Cognition and disability in schizophrenia: cognition-related skills deficits and decision-making challenges add to morbidity","volume":"18","author":"Harvey","year":"2019","journal-title":"World Psychiatry"},{"key":"10.1016\/j.ajp.2026.104979_bib21","doi-asserted-by":"crossref","first-page":"526","DOI":"10.4088\/JCP.11m07162","article-title":"Minimum clinically important difference in the Positive and Negative Syndrome Scale with data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)","volume":"73","author":"Hermes","year":"2012","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ajp.2026.104979_bib22","article-title":"Cochrane handbook for systematic reviews of interventions","volume":"6","author":"Higgins","year":"2024"},{"key":"10.1016\/j.ajp.2026.104979_bib23","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/schbul\/sbp006","article-title":"The dopamine hypothesis of schizophrenia: version III\u2014the final common pathway","volume":"35","author":"Howes","year":"2009","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.ajp.2026.104979_bib24","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1176\/appi.ajp.2020.177901","article-title":"The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia","volume":"177","author":"Keepers","year":"2020","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ajp.2026.104979_bib25","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/schbul\/sbj053","article-title":"The NIMH-MATRICS consensus statement on negative symptoms","volume":"32","author":"Kirkpatrick","year":"2006","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.ajp.2026.104979_bib26","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.euroneuro.2013.06.007","article-title":"The motivation and pleasure dimension of negative symptoms: neural substrates and behavioral outputs","volume":"24","author":"Kring","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.ajp.2026.104979_bib27","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.npp.1301147","article-title":"Linking the PANSS, BPRS, and CGI: clinical implications","volume":"31","author":"Leucht","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ajp.2026.104979_bib28","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of Brief Psychiatric Rating Scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.ajp.2026.104979_bib29","doi-asserted-by":"crossref","first-page":"e668","DOI":"10.4088\/JCP.16r11119","article-title":"The US Food and Drug Administration\u2019s perspective on the new antipsychotic pimavanserin","volume":"78","author":"Mathis","year":"2017","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ajp.2026.104979_bib30","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.tins.2018.12.004","article-title":"Schizophrenia, dopamine and the striatum: from biology to symptoms","volume":"42","author":"McCutcheon","year":"2019","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.ajp.2026.104979_bib31","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/FBP.0b013e32834aff98","article-title":"Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson\u2019s disease","volume":"22","author":"McFarland","year":"2011","journal-title":"Behav. Pharm."},{"key":"10.1016\/j.ajp.2026.104979_bib32","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.schres.2012.07.029","article-title":"Pimavanserin, a selective serotonin (5-HT)2A inverse agonist, enhances the efficacy and safety of risperidone, 2 mg\/day, but does not enhance efficacy of haloperidol, 2 mg\/day: comparison with reference dose risperidone, 6 mg\/day","volume":"141","author":"Meltzer","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.ajp.2026.104979_bib33","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.coph.2011.02.007","article-title":"The role of serotonin receptors in the action of atypical antipsychotic drugs","volume":"11","author":"Meltzer","year":"2011","journal-title":"Curr. Opin. Pharm."},{"key":"10.1016\/j.ajp.2026.104979_bib34","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.euroneuro.2014.03.008","article-title":"Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment","volume":"24","author":"Millan","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.ajp.2026.104979_bib35","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.euroneuro.2020.05.004","article-title":"Pimavanserin exhibits serotonin 5-HT2A receptor inverse agonism for G\u03b1i1- and neutral antagonism for G\u03b1q\/11-proteins in human brain cortex","volume":"36","author":"Muneta-Arrate","year":"2020","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.ajp.2026.104979_bib36","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst. Rev."},{"key":"10.1016\/j.ajp.2026.104979_bib37","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ 372"},{"key":"10.1016\/j.ajp.2026.104979_bib38","unstructured":"Posit team, 2024. RStudio: integrated development environment for R. Posit Software, Boston."},{"key":"10.1016\/j.ajp.2026.104979_bib39","unstructured":"R Core Team, 2025. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna."},{"key":"10.1016\/j.ajp.2026.104979_bib40","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.ajp.2026.104979_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2023.11.015","article-title":"The schizophrenia syndrome, circa 2024: What we know and how that informs its nature","volume":"264","author":"Tandon","year":"2024","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.ajp.2026.104979_bib42","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1124\/jpet.105.097006","article-title":"Pharmacological and behavioral profile of ACP-103, a novel 5-hydroxytryptamine2A receptor inverse agonist","volume":"317","author":"Vanover","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["Asian Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876201826001528?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876201826001528?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T03:32:18Z","timestamp":1779679938000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876201826001528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":42,"alternative-id":["S1876201826001528"],"URL":"https:\/\/doi.org\/10.1016\/j.ajp.2026.104979","relation":{},"ISSN":["1876-2018"],"issn-type":[{"value":"1876-2018","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjunctive pimavanserin in schizophrenia: A systematic review and meta-analysis with a focus on negative-symptom programmes","name":"articletitle","label":"Article Title"},{"value":"Asian Journal of Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajp.2026.104979","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104979"}}